.Pharmacolibrary.Drugs.ATC.L.L04AC25 .Pharmacolibrary.Drugs.ATC.L.L04AC25| name: | Levilimab | |
| ATC code: | L04AC25 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 324 | mg |
| volume of distribution: | 5 | L |
| clearance: | 0.2 | L/h |
| other parameters in model implementation | ||
Levilimab is a human monoclonal antibody targeting the interleukin-6 receptor (IL-6R), developed for the treatment of cytokine release syndrome and severe COVID-19 related pneumonia. It is approved for use in Russia for treatment of severe COVID-19 and is being investigated for other inflammatory conditions.
Pharmacokinetic parameters are estimated for healthy adult subjects based on published monoclonal antibody PK characteristics, as no peer-reviewed clinical PK study for levilimab in humans was found.